GlobalSpace Technologies announces alliance with Pfizer Limited for Vaccine awareness and teleconsultation on DocExa Platform

GlobalSpace Technologies Limited is delighted to announce its strategic partnership with Pfizer, a leading pharmaceutical company for integrating downstream function of providing further valueadded service in the field of Doctor e-consultation facilitation Tab.

Under this agreement, GlobalSpace group would leverage its Makebot platform for vaccine awareness and DocExa platform for consultation by specialists. As a unique value proposition, Globalspace is also setting up a Virtual Adult Vaccine consultation clinics on Docexa platform. This is one of its kind initiative done in the underserved adult vaccination segment. This platform would also provide a customized booking under Doctor e-consultation Tab which will also be hosted on Pfizer's consumer microsite. This Tab will be redirected to an e-consultation page of GlobalSpace which will display relevant doctors who are adult vaccinators (HCPs present on DocExa platform). For this, GlobalSpace will ensure the accuracy of the Data. Pfizer being engaged in the business inter alia of developing, manufacturing and marketing pharmaceutical and consumer healthcare products will help GlobalSpace in expanding its market reach.

This will be a value added component on our current platform where it will further facilitate patients to register themselves for vaccine and DocExa will assign them to nearby authorized doctor. Being an integrated platform, it will directly bring Pfizer's vaccine to the patient through a registered Doctor on a single DocExa platform. The alliance would be a win-win for both DocExa and Pfizer as it would be one of its kind in taking Healthcare especially vaccination program on a technology platform.

Commenting on the new partnership agreement, Mr. Krishna Singh, Founder & CMD said, 'We are glad to announce this strategic alliance with Pfizer,. Currently, this partnership is for one vaccine; however, it could be further extended through all the vaccines which Pfizer has in its portfolio and expected to launch new ones in future. We are very confident about this new initiative. This contract is non-exclusive for DocExa. This is the major breakthrough for our company as we can enter into more and more such kind of partnership with other pharmaceutical companies going forward. This is likely to give us significant growth impetus. Moreover, this will enhance our market reach as the Pfizer being a leading pharmaceutical company will help us in getting a greater number of patients and Doctors on our platform.'

Shares of Globalspace Technologies Ltd was last trading in BSE at Rs.59.45 as compared to the previous close of Rs. 60.25. The total number of shares traded during the day was 2865 in over 28 trades.

The stock hit an intraday high of Rs. 60.6 and intraday low of 59. The net turnover during the day was Rs. 170604.

Source : Equity Bulls

Keywords